

75703

**STIC-Biotech/ChemLib**

---

**From:** Gibbs, Terra  
**Sent:** Friday, September 13, 2002 1:41 PM  
**To:** STIC-Biotech/ChemLib  
**Subject:** Sequence Search

Could you please search SEQ ID NO: 3 of serial number 10/003354

Please do a length limited search of 50 nucleotides or less. Also no EST's.

**Terra Gibbs #79523**  
**AU 1635**  
**Mailbox 11E12**  
**306-3221**

THANK YOU!

Edward Hart  
Technical Info. Specialist  
STIC/Biotech  
CMI 6B02 Tel: 305-9203

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: 9/14/02  
Date Completed: 9/18/02  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH: 1  
NA Sequences: \_\_\_\_\_  
AA Sequences: \_\_\_\_\_  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: W1  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 17, 2002, 22:59:43 ; Search time 4476.82 Seconds  
(without alignments)  
17356.121 Million cell updates/sec

Title: US-10-003-354-3  
Perfect score: 3713  
Sequence: 1 attacagcgccgtgttagt.....aaacttaagtattatta 3713

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues  
Total number of hits satisfying chosen parameters: 708260

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vl:\*  
30: em\_htg\_hum:\*  
31: em\_htg\_inv:\*  
32: em\_htg\_other:\*  
33: em\_htgo\_inv:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result Query SUMMARIES  
No. Score Match Length DB ID Description

1	28.8	0.8	49	6	A59476	A59476 Sequence 26
2	28.8	0.8	49	6	A59509	A59509 Sequence 59
3	22.6	0.6	50	6	AX156774	AX156774 Sequence
4	22.2	0.6	50	23	E09698	E09698 Rigid white
5	21.4	0.6	35	6	A84538	A84538 Sequence 10
6	21.4	0.6	38	6	AX352053	AX352053 Sequence
7	21.2	0.6	50	6	AX159492	AX159492 Sequence
8	21.2	0.6	50	6	AX159494	AX159494 Sequence
9	21.2	0.6	50	6	AX159496	AX159496 Sequence
10	21	0.6	43	6	AR069130	AR069130 Sequence
11	21	0.6	45	6	AX172348	AX172348 Sequence
12	20.8	0.6	32	6	I32124	I32124 Sequence 14
13	20.8	0.6	50	6	AX161426	AX161426 Sequence
14	20.8	0.6	50	6	AX199596	AX199596 Sequence
15	20.6	0.6	41	6	AX040470	AX040470 Sequence
16	20.6	0.6	45	6	AR139083	AR139083 Sequence
17	20.6	0.6	48	6	AX229236	AX229236 Sequence
18	20.6	0.6	50	6	AX164855	AX164855 Sequence
19	20.4	0.5	44	11	HUMUT6082A	L30452 Human STS U
20	20.4	0.5	46	6	AX287580	AX287580 Sequence
21	20.4	0.5	47	6	AX114371	AX114371 Sequence
22	20.4	0.5	50	6	AR059785	AR059785 Sequence
23	20.4	0.5	50	6	AX160060	AX160060 Sequence
24	20.4	0.5	50	6	AX160062	AX160062 Sequence
25	20.2	0.5	40	6	AX299737	AX299737 Sequence
26	20.2	0.5	40	6	E04963	E04963 DNA sequence
27	20.2	0.5	40	9	S80703	S80703 gamma delta
28	20.2	0.5	46	6	I42426	I42426 Sequence 17
29	20.2	0.5	47	6	BD004193	BD004193 RNP deriv
30	20.2	0.5	48	6	AX221459	AX221459 Sequence
31	20.2	0.5	48	6	AX221866	AX221866 Sequence
32	20.2	0.5	48	6	AX229252	AX229252 Sequence
33	20.2	0.5	50	6	AR032844	AR032844 Sequence
34	20.2	0.5	50	6	AR032964	AR032964 Sequence
35	20.2	0.5	50	6	AR032965	AR032965 Sequence
36	20.2	0.5	50	6	AX158192	AX158192 Sequence
37	20.2	0.5	50	6	AX261361	AX261361 Sequence
38	20.2	0.5	50	6	I29584	I29584 Sequence 45
39	20.2	0.5	50	6	I29704	I29704 Sequence 57
40	20.2	0.5	50	6	I29705	I29705 Sequence 57
41	20.2	0.5	50	6	I36502	I36502 Sequence 1
42	20.2	0.5	50	6	I91258	I91258 Sequence 45
43	20.2	0.5	50	6	I91378	I91378 Sequence 57
44	20.2	0.5	50	6	I91379	I91379 Sequence 57
45	20.2	0.5	50	6		

## ALIGNMENTS

RESULT 1  
A59476 LOCUS A59476 49 bp DNA  
DEFINITION Sequence 26 from Patent WO9705234.  
ACCESSION A59476  
VERSION A59476.1 GI:3714788  
KEYWORDS  
SOURCE unidentified.  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 49)  
AUTHORS Chamberlain, S., Pook, M.A., Doudney, C., William, E., Hillermann, R.,  
Garcia-Valdecasas, J.J. and C.  
TITLE GENE FOR FRIEDREICH'S ATAXIA  
JOURNAL Patent: WO 9705234-A 26 13-FEB-1997;  
IMPERIAL COLLEGE (GB)  
FEATURES  
source location/Qualifiers  
1..49  
/organism="unidentified"  
/db\_xref="taxon:32644"  
BASE COUNT 15 a 5 c 13 g 16 t  
ORIGIN



```
RESULT 5
AB4538/c 35 bp DNA linear PAT 21-JUN-2000
LOCUS Sequence 10 from Patent WO9845476.
DEFINITION AB4538
ACCESSION AB4538.1 GI:6733457
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 35)
AUTHORS
TITLE
JOURNAL
SUBSTANCE
Patent: WO 9845476-A 10 15-OCT-1998;
INST OF FOOD RESEARCH (GB); SCHWEIZER MICHAEL (GB)
FEATURES
1. .35
source /organism="unidentified"
/db_xref="taxon:32644"
BASE COUNT 22 a 5 c 6 g 2 t
ORIGIN

Query Match 0.6%; Score 21.4; DB 6; Length 35;
Best Local Similarity 80.6%; Pred. No. 1.5e+06;
Matches 25; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2561 cccagcttcctctctctctctctgaa 2591
11 ||||| 11 |||||
Db 33 CCGGCGCTTTTCTTTTCTTTTTCGGA 3

RESULT 6
AX352053 38 bp DNA linear PAT 06-FEB-2002
LOCUS AX352053
DEFINITION Sequence 349 from Patent WO0193902.
ACCESSION AX352053
VERSION AX352053.1 GI:18617336
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct.
artificial sequence.
REFERENCE
1 (sites)
AUTHORS
Mond,J.J., Flora,M. and Kliman,D.M.
TITLE
Immunostimulatory rna/dna hybrid molecules
JOURNAL
Patent: WO 0193902-A 349 13-DEC-2001;
Biosynexus Incorporated (US)
FEATURES
1.38
source Location/Qualifiers
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic HDR"
BASE COUNT 11 a 6 c 6 g 15 t
ORIGIN

Query Match 0.6%; Score 21.4; DB 6; Length 38;
Best Local Similarity 80.6%; Pred. No. 1.5e+06;
Matches 25; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1221 tacaagacatcctgagtctttttgga 1251
11 ||||| 11 |||||
Db 1 TCCATGACGTCCTCGATGCTTTTGTGCA 31

RESULT 7
AX159492 50 bp DNA linear PAT 22-JUN-2001
LOCUS AX159492
DEFINITION Sequence 2820 from Patent WO0140521.
ACCESSION AX159492
```

```
VERSION AX159492.1 GI:14540823
KEYWORDS
SOURCE
ORGANISM
human.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 (bases 1 to 50)
AUTHORS
Shinkets,R.A. and Leach,M.
TITLE
Nucleic acids containing single nucleotide polymorphisms and
methods of use thereof
JOURNAL
Patent: WO 0140521-A 2820 07-JUN-2001;
Curagen Corporation (US)
FEATURES
1.50
source /organism="Homo sapiens"
/db_xref="taxon:9606"
misc_feature 25..26
/note="Nucleotide deleted between bases 25 and 26
Accession number cg42513366"
BASE COUNT 9 a 8 c 7 g 26 t
ORIGIN

Query Match 0.6%; Score 21.2; DB 6; Length 50;
Best Local Similarity 76.5%; Pred. No. 1.8e+06;
Matches 26; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2564 agcttcctctctctctctctgaaaaag 2597
11 ||||| 11 |||||
Db 3 AGTTGCTTTTGTCTTTTAAAGACAG 36

RESULT 8
AX159494 50 bp DNA linear PAT 22-JUN-2001
LOCUS AX159494
DEFINITION Sequence 2822 from Patent WO0140521.
ACCESSION AX159494
VERSION AX159494.1 GI:14540825
KEYWORDS
SOURCE
ORGANISM
human.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 (bases 1 to 50)
AUTHORS
Shinkets,R.A. and Leach,M.
TITLE
Nucleic acids containing single nucleotide polymorphisms and
methods of use thereof
JOURNAL
Patent: WO 0140521-A 2822 07-JUN-2001;
Curagen Corporation (US)
FEATURES
1.50
source Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
misc_feature 25..26
/note="Nucleotide deleted between bases 25 and 26
Accession number cg42513366"
BASE COUNT 9 a 8 c 7 g 26 t
ORIGIN

Query Match 0.6%; Score 21.2; DB 6; Length 50;
Best Local Similarity 76.5%; Pred. No. 1.8e+06;
Matches 26; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2564 agcttcctctctctctctctgaaaaag 2597
11 ||||| 11 |||||
Db 2 AGTTGCTTTTGTCTTTTAAAGACAG 35
```

Query Match	0.6%	Score 21.2	DB 6	Length 50
Best Local Similarity	76.5%	Pred. No. 1.8e+06		
Matches	26	Conservative	0	Mismatches 8; Indels 0; Gaps 0;
QY	2564	agcttcctctctctcttttttttctcgaaaaaag	2597	
DB	1	AGTTTGGCTTTTGGTTTTTTTTTTTAAAGCAAGG	34	

Query Match	0.6%	Score 21	DB 6	Length 43
Best Local Similarity	73.0%	Pred. NO. 2e+06		
Matches	27	Conservative	0	Mismatches 10; Indels 0; Gaps 0;
Qy	2567	ttctctctctcttcttcttcgaaaaaggaagaag	2603	
Db	42	TTTTTTTTTTTTTTTTTTAGTGAATGACATAAAG	6	
RESULT	11			
LOCUS	AX172348	45 bp	DNA	linear
DEFINITION	Sequence 1 from Patent WO0144811.			PAT 03-JUL-2001

```

Query Match 0.6%; Score 21; DB 6; Length 45;
Best Local Similarity 66.7%; Pred. No. 2e+06;
Matches 30; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Ox 2568 tctctctctctttttttctgaaaaaaggaaagcacacagca 2612
1 tttttttttttttttttttttcttAAAAAGAGCCCTTCATATGGGA 45

```

Query Match	Score 20.8;	DB 6;	Length 32;
Best Local Similarity	78.1%;	Pred. No. 2.2e+06;	
Matches	25;	Conservative	0; Mismatches 7; Indels 0; Gaps 0;
QY	2555	ccacatccacgctctctctctctctctctt	2586
Db	1	CCGCGTCGTCGCGCTTTTTTTTTTTTTTTT	32

RESULT	13				
AX161426/c					
LOCUS					
DEFINITION	AX161426	50 bp	DNA	linear	PAT 22-JUN-2001
ACCESSION	Sequence 4754 from Patent WO0140521.				
VERSION	AX161426				
KEYWORDS	AX161426.1	GI:14542757			
SOURCE	human.				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1 (bases 1 to 50)				
AUTHORS	Shinkels, R.A. and Leach, M.				

TITLE Nucleic acids containing single nucleotide polymorphisms and methods of use thereof  
JOURNAL Patent: WO 0140521-A 4754 07-JUN-2001;  
Curagen Corporation (US)  
FEATURES Location/Qualifiers  
source 1..50  
misc-feature /organism="Homo sapiens"  
/db\_xref="taxon:9606"  
25..26  
/note="Nucleotide deleted between bases 25 and 26  
Accession number cg4396965"  
misc-feature 26  
/note="2 of 2 allelic variants (4753 is other entry)"  
BASE COUNT 20 a 6 c 12 g 12 t  
ORIGIN

Query Match 0.6%; Score 20.8; DB 6; Length 50;  
Best Local Similarity 78.1%; Pred. No. 2.3e+06;  
Matches 25; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3682 tttaatgataacttaactgaattattta 3713  
||||| ||| ||||| ||||| |||||  
Db 50 tttttctgcacgacaccttaatgaccttttga 19

RESULT 14  
AX199596/c 50 bp DNA linear PAT 29-AUG-2001  
LOCUS AX199596  
DEFINITION Sequence 526 from Patent WO0151670.  
ACCESSION AX199596  
VERSION AX199596.1 GI:15390030  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
REFERENCE 1 (bases 1 to 50)  
AUTHORS Shinkets, R.A. and Leach, M.D.  
TITLE Nucleic acids containing single nucleotide polymorphisms and methods of use thereof  
JOURNAL Patent: WO 0151670-A 526 19-JUL-2001;  
Curagen Corporation (US)  
FEATURES Location/Qualifiers  
source 1..50  
misc-feature /organism="Homo sapiens"  
/db\_xref="taxon:9606"  
25..26  
/note="Nucleotide deleted between bases 25 and 26  
Accession number cg42855114"  
misc-feature 26  
/note="2 of 2 allelic variants (525 is other entry)"  
BASE COUNT 20 a 8 c 10 g 12 t  
ORIGIN

Query Match 0.6%; Score 20.8; DB 6; Length 50;  
Best Local Similarity 64.6%; Pred. No. 2.3e+06;  
Matches 31; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 2307 gatttcaactggcaacctgtcctcaacttaatttttcag 2354  
||||| ||| ||| ||||| ||||| |||||  
Db 48 GAGTTTCATCTCTGACGACGATGACACCAATTTTTCATTTTCTCG 1

RESULT 15  
AX040470/c 41 bp DNA linear PAT 18-NOV-2000  
LOCUS AX040470  
DEFINITION Sequence 10 from Patent WO0063365.  
ACCESSION AX040470  
VERSION AX040470.1 GI:11230262  
KEYWORDS  
SOURCE synthetic construct.

ORGANISM synthetic construct  
artificial sequence.  
REFERENCE 1 (bases 1 to 41)  
AUTHORS Beloserkovskii, B., Reddy, G. and Zarling, D.  
TITLE Locked nucleic acid hybrids and methods of use  
JOURNAL Patent: WO 0063365-A 10 26-OCT-2000;  
Pangene Corporation (US)  
FEATURES Location/Qualifiers  
source 1..41  
misc-feature /organism="synthetic construct"  
/db\_xref="taxon:32630"  
/note="Triplex forming DNA"  
BASE COUNT 7 a 25 c 2 g 7 t  
ORIGIN

Query Match 0.6%; Score 20.6; DB 6; Length 41;  
Best Local Similarity 74.3%; Pred. No. 2.6e+06;  
Matches 26; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 3566 ggaaggctgggtcttgggaaggaatgggaagc 3600  
||||| ||||| ||||| ||||| |||||  
Db 36 GGTGGGTGGGGTATTAAGCGAGGAGGAGGAGC 2

Search completed: September 18, 2002, 01:15:45  
Tot Time: 8162 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 17, 2002, 23:03:38 : Search time 382.89 Seconds  
(without alignments)  
16649.438 Million cell updates/sec

Title: US-10-003-354-3

Perfect score: 3713

Sequence: 1 attacagcgcgtgcttagg.....aaacttaatgattattta 3713

Scoring table: IDENTITY\_NUC

Gapop 10.0, Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 1905168

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: N\_Geneseq\_032802.\*

```
1: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	28.8	0.8	49	18	AAT84374	Friedreich's ataxi
2	24.8	0.7	50	22	AA130887	Human SNP oligonuc
3	24.6	0.7	50	22	AA131735	Human SNP oligonuc
4	22.6	0.6	45	16	AA090968	(Set4G1Y)2 linker
5	22.6	0.6	45	21	AA112866	DNA encoding (Ser4
6	22.6	0.6	40	22	AA173161	Human silent SNP c
7	22.2	0.6	40	22	AAH20340	HHV6 virus p41 gen
8	22.2	0.6	48	22	AA130218	Human SNP oligonuc
9	22.2	0.6	50	16	AA087804	Ige receptor beta

10	22	0.6	48	16	AAT04081	Trypsin inhibitory
11	22	0.6	50	22	AA134072	Human SNP oligonuc
12	21.8	0.6	50	22	AA128913	Human SNP oligonuc
13	21.6	0.6	40	22	AAH20339	HHV6 virus p41 gen
14	21.6	0.6	50	20	AAH31293	Human SNP oligonuc
15	21.6	0.6	35	20	AAV83644	Oligonucleotide us
16	21.2	0.6	47	22	AA130217	Human SNP oligonuc
17	21.2	0.6	50	22	AA127921	Human SNP oligonuc
18	21.2	0.6	50	22	AA128580	Human SNP oligonuc
19	21.2	0.6	50	22	AA175879	Human silent SNP c
20	21.2	0.6	50	22	AA175881	Human silent SNP c
21	21.2	0.6	50	22	AA175883	Human silent SNP c
22	21	0.6	44	22	AA128737	Human SNP oligonuc
23	21	0.6	45	20	AA231524	Probe for HIV RNA
24	21	0.6	45	20	AA211012	Probe #1 for HIV t
25	21	0.6	45	22	AA181851	Probe #1 used for
26	21	0.6	46	20	AAH77169	Chimeric packaging
27	20.8	0.6	47	21	AA267568	Human map-related
28	20.8	0.6	50	22	AA128914	Human SNP oligonuc
29	20.8	0.6	50	22	AA177813	Human silent SNP c
30	20.8	0.6	50	22	AAH89745	Human coding sequ
31	20.6	0.6	27	20	AAH23570	Deletion sequence
32	20.6	0.6	41	21	AAH66740	Probe pT1. Uniden
33	20.6	0.6	45	16	AA080709	Drosophila hsp70 g
34	20.6	0.6	45	22	AAH89633	S. cerevisiae YKR0
35	20.6	0.6	47	21	AA267659	Human map-related
36	20.6	0.6	48	22	AAH97394	Human Chk1 ribozym
37	20.6	0.6	50	22	AAH29036	Human SNP oligonuc
38	20.6	0.6	50	22	AAH30220	Human SNP oligonuc
39	20.6	0.6	50	23	AAH00059	Human silent nonco
40	20.4	0.5	40	15	AA055168	Sequence of primer
41	20.4	0.5	41	20	AAH34851	Primer for adapter
42	20.4	0.5	41	20	AAH23455	Human neutrophil c
43	20.4	0.5	46	24	AAH95733	Allele discriminat
44	20.4	0.5	47	21	AA267078	Human map-related
45	20.4	0.5	47	21	AA267213	Human map-related

#### ALIGNMENTS

RESULT 1	
ID AAT84374	standard; DNA; 49 Bp.
AC AAT84374;	
XX	
DT 12-NOV-1997	(first entry)
XX	
DE Friedreich's ataxia STM7 gene exon 11.	
XX	
KW STM7.I gene; Friedreich's ataxia; FRDA; neurodegeneration;	
KW phosphatidylinositol-4-phosphate 5-kinase; Ptdinspk;	
KW transgenic animal; animal model; diagnosis; therapy;	
KW STM7.IIra; STM7.IIib; STM7.IIic; ss.	
XX	
OS Homo sapiens.	
XX	
PN WO9705234-A2.	
XX	
PD 13-FEB-1997.	
XX	
PF 24-JUL-1996;	96WO-GB01786.
XX	
PR 28-JUL-1995;	95GB-0015508.
XX	
PR 26-JUL-1995;	95GB-0015309.
XX	
PA (UNLO ) IMPERIAL COLLEGE SCI TECHNOLOGY & MED.	
XX	
PI Chamberlain S, Doudney CWE, Garcia-Valdecasas JJC;	
XX	
PI Hillermann R, Pook MA;	
XX	
DR WPI; 1997-145674/13.	

XX New gene, *STM7*, and new protein causing Friedreich's Ataxia -  
 PT encodes phosphatidylinositol phosphate isoform; also splice  
 PT variants and transgenic animals, for diagnosing pre-disposition to  
 PT Friedreich's ataxia  
 XX  
 PS Claim 1; Fig 16; 82pp; English.  
 XX  
 CC DNA sequences (AA784364-86) are provided for exons 1-23,  
 CC respectively, of the human *STM7* gene associated with Friedreich's  
 CC ataxia (FRDA). The *STM7*.1 gene (see AA784358) comprises exons  
 CC 1-16 of the gene, while splice variant *STM7*.IIIIa includes exons  
 CC 1-13, 17 and 19-22, splice variant *STM7*.IIIIb includes exons  
 CC 1-15, 17, 19, 21-22 and splice variant *STM7*.IIIIc includes exons  
 CC 1-15 and 19-22. *STM7* nucleic acids can be used to produce *STM7*  
 CC polypeptides (see AA000978) in transfected host cells, to design  
 CC probes (esp. oligonucleotides) from exons 1-16, partic. 7-11) used  
 CC in a claimed method for determining an inherited predisposition to  
 CC FRDA, to generate transgenic animal models of FRDA and in somatic  
 CC cell therapy.  
 CC  
 XX Sequence 49 BP; 15 A; 5 C; 13 G; 16 T; 0 other;  
 SQ  
 Query Match 0.8%; Score 28.8; DB 18; Length 49;  
 Best Local Similarity 75.0%; Pred. No. 4e+02;  
 Matches 36; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
 OY 1591 gttgttaagaagtgtgagacactcttgaaagccctggtacatacg 1638  
 ||| | ||||| || || || ||||| || || || || ||  
 Db 1 gtaataagaagtagtagacattctcttgaaagccctggtatgatg 48  
 RESULT 2  
 ID AAL30887/c  
 AC AAL30887 standard; DNA: 50 BP.  
 XX  
 AC AAL30887;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE Human SNP oligonucleotide #4095.  
 XX  
 KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;  
 KW neuroprotective; antimicrobial; gene therapy; vaccine; cancer;  
 KW amyloid protein; angiotensin; apoptosis related protein; cadherin;  
 KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;  
 KW complement related protein; cytochrome; kinesin; cytokine; interferon;  
 KW interleukin; G-protein coupled receptor; thioesterase; inflammation;  
 KW multifactorial disease; autoimmune disease; infection;  
 KW nervous system disease; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 OS Homo sapiens.  
 PN WO200147944-A2.  
 XX  
 PD 05-JUL-2001.  
 XX  
 PD 28-DEC-2000; 2000MO-US35498.  
 XX  
 PF 28-DEC-1999; 99US-0173419.  
 PR 27-DEC-2000; 2000US-0173419.  
 XX  
 PA (CURA-) CURAGEN CORP.  
 XX  
 PI Shimkets RA, Leach M;  
 DR WPI; 2001-465210/50.  
 XX  
 PT Polymorphic nucleic acids encoding e.g. amyloses, cyclins, polymerases,  
 PT oncogenes and histones, useful for diagnosing and treating, e.g.  
 PT cancer, autoimmune diseases and infections -  
 XX  
 XX

PS Claim 1; Page 2562; 4143pp; English.  
 XX  
 CC The present invention relates to oligonucleotides encoding polymorphic  
 CC variants of proteins related to amyloses, amyloid proteins, angiotensin,  
 CC apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,  
 CC histones, kinases, colony stimulating factors, complement related  
 CC proteins, cytochromes, kinesins, cytokines, interferons, interleukins,  
 CC G-protein coupled receptors and thioesterases. The present sequence is  
 CC one such oligonucleotide. The oligonucleotides and the peptides encoded  
 CC by them may be used in the prevention, diagnosis and treatment of  
 CC diseases associated with inappropriate expression of the proteins listed  
 CC above. Disorders that may be prevented, diagnosed and/or treated include  
 CC multifactorial diseases with a genetic component, such as autoimmune  
 CC diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,  
 CC systemic lupus erythematosus and Grave's disease), inflammation, cancer  
 CC (e.g. cancers of the bladder, brain, breast, colon and kidney,  
 CC leukaemia), diseases of the nervous system and an infection of pathogenic  
 CC organisms.  
 CC  
 XX Sequence 50 BP; 16 A; 3 C; 6 G; 25 T; 0 other;  
 SQ  
 Query Match 0.7%; Score 24.8; DB 22; Length 50;  
 Best Local Similarity 72.7%; Pred. No. 5.5e+03;  
 Matches 32; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
 OY 2577 tttttttctgaaaaaagaaagcacagcacacatt 2620  
 | ||||| ||||| ||| | ||||| ||  
 Db 44 TCTTTTAAAAAAGCAAAAAGCATATCAACATATT 1  
 RESULT 3  
 ID AAL31735  
 AC AAL31735 standard; DNA: 50 BP.  
 XX  
 AC AAL31735;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE Human SNP oligonucleotide #4943.  
 XX  
 KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;  
 KW neuroprotective; antimicrobial; gene therapy; vaccine; cancer;  
 KW amyloid protein; angiotensin; apoptosis related protein; cadherin;  
 KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;  
 KW complement related protein; cytochrome; kinesin; cytokine; interferon;  
 KW interleukin; G-protein coupled receptor; thioesterase; inflammation;  
 KW multifactorial disease; autoimmune disease; infection;  
 KW nervous system disease; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 OS Homo sapiens.  
 PN WO200147944-A2.  
 XX  
 PD 05-JUL-2001.  
 XX  
 PD 28-DEC-2000; 2000MO-US35498.  
 XX  
 PF 28-DEC-1999; 99US-0173419.  
 PR 27-DEC-2000; 2000US-0173419.  
 XX  
 PA (CURA-) CURAGEN CORP.  
 XX  
 PI Shimkets RA, Leach M;  
 DR WPI; 2001-465210/50.  
 XX  
 PT Polymorphic nucleic acids encoding e.g. amyloses, cyclins, polymerases,  
 PT oncogenes and histones, useful for diagnosing and treating, e.g.  
 PT cancer, autoimmune diseases and infections -  
 XX  
 XX Claim 1; Page 2809; 4143pp; English.  
 XX

CC	Intraocular availability of the TA. The conjugates of the invention
CC	are used to inhibit cell proliferation in cells carrying the
CC	particular growth factor receptor; also when TA is DNA it can be used
CC	to deliver this to cells (for gene therapy). A specific application
CC	is to prevent excessive proliferation of epithelial cells,
CC	fibroblasts and keratinocytes in the anterior eye after surgery,
CC	partic. to prevent recurrence of pterygii after surgical removal,
CC	closure of trabeculectomy after glaucoma surgery and corneal clouding
CC	after excimer laser treatment. Other conditions which may be treated
CC	include tumours, stenosis, psoriasis, Dupuytren's contracture,
CC	diabetic complications, Kaposi's sarcoma and rheumatoid arthritis.
XX	
SQ	Sequence 45 BP; 2 A; 16 C; 17 G; 10 T; 0 other;
OY	
DB	
Query Match	0.6%; Score 22.6; DB 16; Length 45;
Best Local Similarity	75.7%; Pred. No. 2.2e+04;
Matches 28; Conservative	0; Mismatches 9; Indels 0; Gaps 0;
401 atggcgtcgccctccgcgcgcgcgtcgttcgtcg 437	
3 atggcctcgtcgtcgtcgtcgccgcgcgtcgtcgagcg 39	
RESULT 5	
AAAI2866	
AAAI2866 standard; DNA: 45 BP.	
AC AAAI2866;	
DT 18-JUL-2000 (first entry)	
XX	
DE DNA encoding (Ser4-Gly)2 flexible linker peptide, SEQ ID NO:50.	
XX	
KM Targetted gene delivery; fibroblast growth factor receptor;	
KM FGF-binding protein; nucleic acid binding protein;	
KM receptor-internalised ligand; cytotoxin; saporin; gene therapy;	
KM cycloide; antiproliferative; cancer; melanoma; diabetic retinopathy;	
KM rheumatoid arthritis; restenosis; Dupuytren's contracture; psoriasis;	
KM eczema; nuclear translocation signal; NRS;	
KM cytoplasmic translocation signal; endosome-disruptive peptide; ss.	
XX	
OS Synthetic.	
XX	
PN US6037329-A.	
XX	
PD 14-MAR-2000.	
PF 24-SEP-1996; 96US-0718904.	
XX	
PR 15-MAR-1994; 94US-0213446.	
PR 15-MAR-1994; 94US-0213447.	
PR 29-AUG-1994; 94US-0287961.	
PR 13-SEP-1994; 94US-0305771.	
PR 16-MAY-1995; 95US-0441979.	
XX	
PA (SELE-) SELECTIVE GENETICS INC.	
XX	
PI Chandler LA, Sosnowski BA, Baird JA;	
DR WPI; 2000-292008/25.	
XX	
PT Gene delivery system, useful for treating or preventing cancer and	
PT Rheumatoid arthritis, comprises receptor-internalized ligand linked to	
PT nucleic acid binding domain and nucleic acid -	
XX	
PS Claim 21; Column 33; 131pp; English.	
XX	
CC The invention relates to a novel gene delivery composition for the	
CC targeted delivery of cytotoxins or prodrug-converting enzymes to	
CC proliferating cells. The gene delivery composition comprises a protein	
CC that binds the fibroblast growth factor receptor (FGFR) which is fused	
CC or chemically conjugated to a nucleic acid binding domain. The nucleic	

CC acid binding domain is complexed with a suitable expression construct  
CC encoding a cytotoxin such as saporin. One or more linkers may join the  
CC FcFR-binding protein to the nucleic acid binding protein. These are  
CC selected to increase the specificity, toxicity, solubility, serum  
CC stability or intracellular availability, and may serve to promote  
CC condensation of nucleic acids for delivery to a cell. The fusion protein  
CC binds to FcFR and is internalised by cells that carry this receptor. The  
CC gene delivery composition is used for the therapeutic alteration of the  
CC function, gene expression and viability of cells. In particular, it may  
CC be used for the treatment and prevention of cell proliferative  
CC disorders, for example after eye surgery, melanoma and many other sorts  
CC of cancer, rheumatoid arthritis, psoriasis and eczema. The gene delivery  
CC compositions of the invention have high specificity for particular cells  
CC and can deliver larger amounts of DNA compared to prior art methods.  
CC Sequences AA190424-AA190441 represent nuclear translocation signals  
CC (NLSs) from a variety of proteins, and AA190442-Y90444 represent  
CC cytoplasmic translocation signals. Sequences AA12863-A12867 encode flexible  
CC linker peptides, AA190447 being a claimed linker peptide. AA12882-A12887  
CC encode linkers that are substrates for certain enzymes, AA190451-Y90453  
CC being examples of such linkers.

SQ Sequence 45 BP; 2 A; 16 C; 17 G; 10 T; 0 other;

Query Match 0.6%; Score 22.6; DB 21; Length 45;  
Best Local Similarity 75.7%; Pred. No. 2.2e+04;  
Matches 28; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

OY 401 atgagctgcgcctcctccgagcgctgcgtcg 437  
||||| ||| | | | | | | | | | | | | | | | |  
Db 3 atgagctgcgtcgtcgctgcgtcgctcg 39

## RESULT 6

AA173161  
ID AA173161 standard; DNA; 50 BP.

AC AA173161;

DT 09-NOV-2001 (first entry)

DE Human silent SNP containing nucleic acid SEQ:102.

XX Human; single nucleotide polymorphism; SNP; genome; gene therapy;

KW protein therapy; vaccine; probe; diagnostic assay; detection;

KW quantitation; restorative therapy; polymorphic; ds.

XX Homo sapiens.

GS WO200140521-A2.

PN 07-JUN-2001.

PD 30-NOV-2000; 2000MO-US32758.

PF 30-NOV-1999; 99US-0168138.

PR 29-NOV-2000; 2000US-0726173.

XX (CURA-) CURAGEN CORP.

XX Shinkets RA, Leach M;

XX WPI; 2001-356160/37.

XX Polymorphic nucleic acid sequences, useful in genetic testing and

XX therapy -

XX Claim 1; Page 85; 2653pp; English.

XX AA173060 to AA179867 represent isolated human polymorphic polynucleotide

XX sequences (I), which contain single nucleotide polymorphisms (SNPs).

CC AA53114 to AA53329 represent peptides related to human polymorphic  
CC polynucleotide sequences. The sequences can be used in gene and protein  
CC therapy, and in vaccine production. (I) and the polypeptides encoded by  
CC them may be used in the prevention, diagnosis and treatment of diseases  
CC associated with inappropriate expression of polymorphic polypeptides.  
CC For example, (I) may be used to treat disorders by rectifying mutations  
CC or deletions in a patient's genome that affect the activity of  
CC polypeptides by expressing inactive proteins or to supplement the  
CC patient's own production of polypeptide. Additionally, (I) and its  
CC complementary sequences may also be used as DNA probes in diagnostic  
CC assays to detect and quantitate the presence of similar nucleic acids  
CC in samples, and therefore which patients may be in need of restorative  
CC therapy. The polypeptides encoded by (I) may be used as antigens in the  
CC production of antibodies specific for polymorphic polypeptides. The  
CC antibodies may also be used to down regulate expression and activity.  
CC The antibodies may also be used as diagnostic agents for detecting the  
CC presence of polymorphic polypeptides in samples.

SQ Sequence 50 BP; 8 A; 10 C; 3 G; 29 T; 0 other;

Query Match 0.6%; Score 22.6; DB 22; Length 50;  
Best Local Similarity 75.7%; Pred. No. 2.3e+04;  
Matches 28; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

OY 2560 tccagcttcctcctcttttttttcgaaaaag 2596  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 tcttgcttccttccttccttttttcaataacaag 37

## RESULT 7

AAH20340  
ID AAH20340 standard; DNA; 40 BP.

AC AAH20340;

DT 01-AUG-2001 (first entry)

DE HHV6 virus p41 gene specific primer p41FH92 SEQ ID 21.

XX Primer; solid phase amplification of DNA template; SPADT; detection; RGP;

KW genomic scanning; bacterial diagnostic; p41; HHV6; ss.

XX Human herpesvirus 6.

OS Synthetic.

PN US6221635-B1.

PD 24-APR-2001.

PF 06-MAY-1999; 99US-0306290.

PR 06-MAY-1999; 99US-0306290.

XX (WIST-) WISTAR INST.

XX Rovera G, Mukhopadhyay S;

XX WPI; 2001-315577/33.

XX Detecting the presence of a specific nucleic acid in a sample

XX containing DNA, useful in scanning large genomic fragments for the

XX presence of genes or gene families, comprises performing solid phase

XX amplification of DNA template -

XX Example 2; Column 28; 49pp; English.

XX This invention relates to a method for detecting the presence of a

XX specific nucleic acid in a sample containing DNA. The method comprises

XX performing solid phase amplification of DNA template (SPADT). 5' and 3'

XX primers are irreversibly bound to a solid support, and the DNA from a

XX sample is absorbed and reversibly bound, incubated under amplification

XX reaction conditions and the presence of the specific target DNA is

Sequence 40 BP; 9 A; 2 C; 4 G; 25 T; 0 other;

Qy 2568 ttcttcttcttttttttctgaaaaaagyaaaa 2602

Db 1 ttttttttttttttttgaagctgaaaa 35

```

RESULT      8
AAL30218
ID   AAL30218 standard; DNA; 48 BP

```

AC AAL30218;

DT 24-JAN-2002 (first entry)

Human SNP oligonucleotide #3426.

KW immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;  
 KW neuroprotective; antimicrobial; gene therapy; vaccine; amylose; cancer;  
 KW amyloid protein; angiotensin; apoptosis related protein; cadherin;  
 KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor  
 KW complement related protein; cytochrome; kinesin; cytokine; interferon;  
 KW interleukin; G-protein coupled receptor; thioesterase; inflammation;  
 KW multifactorial disease; autoimmune disease; infection;  
 KW nervous system disease; ss

OS Homo sapiens

PN WO200147944-A2.

PD 05-JUL-2001.

PF 28-DEC-2000; 2000WO-US35498

PR 28-DEC-1999; 99US-0173419

XX

PA (CURA-) CURAGEN CORP

PI Shimkets RA, Leach M;

DR WPI; 2001-465210/50.

PT Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,

PT cancer, autoimmune diseases and infections -

PS Claim 1; Page 2369; 4143pp; English

CC The present invention relates to oligonucleotides encoding polymorphic  
CC variants of proteins related to amylases, amyloid proteins, angiotensin  
CC converting related proteins, cadherin, cyclin, polymerase, oncogenes,  
CC apoptosis related proteins, cathepsin, cyclin, polymerase, oncogenes,  
CC histones, kinases, colony stimulating factors, complement related  
CC proteins, cytochromes, kinesins, cytokines, interleukins, interleukins,  
CC G-protein coupled receptors and cholinesterases. The present sequence is  
CC one such oligonucleotide. The oligonucleotides and the peptides encoded

by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate expression of the proteins listed above. Disorders that may be prevented, diagnosed and/or treated include multifactorial diseases with a genetic component, such as autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus erythematosus and Grave's disease), inflammation, cancer (e.g. cancers of the bladder, brain, breast, colon and kidney, leukemia), diseases of the nervous system and an infection of pathogenic organisms.

Sequence 48 BP; 7 A; 9 C; 1 G; 31 T; 0 other,

Query Match	0.6%	Score 22.2;	DB 22,	Length 48;
Best Local Similarity	69.8%;	Pred. No. 2.9e+04;		
Matches 30; Conservative	0;	Mismatches 13;	Indels 0;	Gaps 0;

QY 3473 ttgctatttttttcataattactattatgatttta 3515

Db 6 ttttttttttttttactttcctacatcagtttattta 48

RESULT	9
AAQ87804	
ID	AAQ87804 standard; DNA; 50 BP

AC AAQ87804

DT 14-NOV-1995 (first entry)

DE IGE receptor beta chain ligand.

KW Probe; immunoglobulin; IgE; receptor; beta; allergic disease;

KW detection; screening; diagnosis; ss.

05 Synthetic.

FH	Key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

```

ET      /*tag= a

```

(product of ABI company)

PN EP649910-A.

PD 26-APR-1995.

PF 21-OCT-1994; 94EP-0307751

PR 22-OCT-1993; 93JP-0265144

PA (SUME ) SUMITOMO ELECTRIC IND CO.

PI Miyabe Y, Nakata M, Osoegawa M, Ra C, Suzuki K;

DR WPI; 1995-156760/21.

PT	Probes for mutation(s) in beta chain gene of a high affinity IgE
PT	receptor - for the diagnosis of allergic disease, esp. in
PT	neonate(s)

PS Claim 8; Page 8; 17pp; English

CC DNA primers (See AAC87799-803) having sequences identical or  
CC complementary to parts of the immunoglobulin E (IgE) receptor, are  
CC used to detect genes associated with allergic diseases (genes  
CC involving mutations in the beta chain gene). This sequence is used in  
CC neonatal screening, prenatal diagnosis etc. This sequence is an  
CC IgE ligand which is immobilised on a support and used to bind to  
CC probe/IgE receptor gene conjugates. The probe is then eluted by a  
CC gradual rise in temperature.

SQ Sequence 50 BP; 12 A; 17 C; 10 G; 11 T; 0 other;



KM	neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
KM	amyloid protein; antidiabetic; apoptosis related protein; cadherin;
KM	cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KM	complement related protein; cytochrome; kinesin; cytokine; interferon;
KM	interleukin; G-protein coupled receptor; thioesterase; inflammation;
KM	multifactorial disease; autoimmune disease; infection;
KM	nervous system disease; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200147944-A2.
XX	
PD	05-JUL-2001.
XX	
PF	28-DEC-2000; 2000WO-US35498.
XX	
PR	28-DEC-1999; 99US-0173419.
XX	
PR	27-DEC-2000; 2000US-0173419.
XX	
PA	(CURA-) CURAGEN CORP.
XX	
PI	Shinkets RA, Leach M;
XX	
DR	WPI; 2001-465210/50.
XX	
PT	Polyomorph nucleic acids encoding e.g. amylases, cyclins, polymerases,
PT	oncogenes and histones, useful for diagnosing and treating, e.g.
PT	cancer, autoimmune diseases and infections -
XX	
PS	Claim 1; Page 1988; 4143pp; English.
XX	
CC	The present invention relates to oligonucleotides encoding polymorphic
CC	variants of proteins related to amylases, amyloid proteins, angiotensin,
CC	apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,
CC	histones, kinases, colony stimulating factors, complement related
CC	proteins, cytochromes, kinesins, cytokines, interferons, interleukins,
CC	G-protein coupled receptors and thioesterases. The present sequence is
CC	one such oligonucleotide. The oligonucleotides and the peptides encoded
CC	by them may be used in the prevention, diagnosis and treatment of
CC	diseases associated with inappropriate expression of the proteins listed
CC	above. Disorders that may be prevented, diagnosed and/or treated include
CC	multifactorial diseases with a genetic component, such as autoimmune
CC	diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,
CC	systemic lupus erythematosus and Grave's disease), inflammation, cancer
CC	(e.g. cancers of the bladder, brain, breast, colon and kidney,
CC	leukaemia), diseases of the nervous system and an infection of pathogenic
CC	organisms.
XX	
SQ	Sequence 50 BP; 13 A; 11 C; 14 G; 12 T; 0 other;
	Query Match            0.6%; Score 21.8; DB 22; Length 50;
	Best Local Similarity   78.8%; Pred. No. 3.9e+04;
Matches	26; Conservative     0; Mismatches     7; Indels     0; Gaps     0;
OY	2007 ccttggaagcgttaagtgcgacgtcagagt 2039
DB	15 ccttggaaagcgcaagtcgtactccgagt 47
RESULT	13
ID	AAH20339 standard; DNA; 40 BP.
XX	
AC	AAH20339;
XX	
DT	01-AUG-2001 (first entry)
XX	
DE	HHV6 virus p41 gene specific primer p41FH6 SEQ ID 20.
KX	Primer: solid phase amplification of DNA template; SPADT; detection; RGP;
KM	genomic scanning; bacterial diagnostic; p41; HHV6; ss.
XX	

OS	Human herpesvirus 6.
OS	Synthetic.
XX	
PN	US6221635-B1.
XX	
PD	24-APR-2001.
XX	
PF	06-MAY-1999; 99US-0306290.
PR	06-MAY-1999; 99US-0306290.
PA	(WIST-) WISTAR INST.
XX	
PI	Rovera G, Mukhopadhyay S;
DR	WPI: 2001-315577/33.
XX	
PT	Detecting the presence of a specific nucleic acid in a sample
PT	containing DNA, useful in scanning large genomic fragments for the
PT	presence of genes or gene families, comprises performing solid phase
PS	amplification of DNA template
XX	
PS	Example 2; Column 28; 49pp; English.
CC	This invention relates to a method for detecting the presence of a
CC	specific nucleic acid in a sample containing DNA. The method comprises
CC	performing solid phase amplification of DNA template (SPADY), 5' and 3'
CC	primers are irreversibly bound to a solid support, and the DNA from a
CC	sample is absorbed and reversibly bound, incubated under amplification
CC	reaction conditions and the presence of the specific target DNA is
CC	detected. The method is useful for detecting the presence of a specific
CC	nucleic acid (e.g. bacterial, viral or parasitic DNA) in a sample or in a
CC	cell. SPADY may be used for scanning large genomic fragments for the
CC	presence of genes or gene families; or for bacterial diagnostics by
CC	examining the ribosomal RNA genes; or for viral diagnostics by scanning
CC	for the presence of viral nucleic acid sequences in a sample. SPADY may
CC	also be used in forensic medicine by detecting and identifying species
CC	specific sequences or for the presence of major histocompatibility
CC	complex. The present sequence represents a primer specific for the human
CC	herpesvirus 6 (HHV6) pLI gene. The primer is used in an example
CC	illustrating the method of the invention.
XX	
SQ	Sequence 40 BP; 9 A; 3 C; 7 G; 21 T; 0 other;
Query Match	0.6%; Score 21.6; DB 22; Length 40;
Best Local Similarity	75.0%; Pred. No. 3.9e+04;
Matches 27; Conservative	0; Mismatches 9; Indels 0; Gaps 0;
YY	2567 ttctcttctcttttttttcgtgaaaaaggaaa 2602
DB	1 ttttttttttttttttttcgcggacatagaga 36
RESULT 14	
ID	AAL31293/c
XX	AAL31293 standard; DNA: 50 BP.
XX	
XX	AAL31293;
DT	24-JAN-2002 (first entry)
DE	
XX	Human SNP oligonucleotide #4501.
KM	Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
KM	neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
KM	amyloid protein; angiotensin; apoptosis related protein; cadherin;
KM	cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KM	complement related protein; cytochrome; kinesin; cytokine; interferon;
KM	interleukin; G-protein coupled receptor; thioesterase; inflammation;
KM	multifactorial disease; autoimmune disease; infection;
KM	nervous system disease; ss.
XX	

XX	Homo sapiens.
PN	MO200147944-A2.
PD	05-JUL-2001.
PF	28-DEC-2000; 2000WO-US35498.
PR	28-DEC-1999; 99US-0173419.
PR	27-DEC-2000; 2000US-0173419.
PA	(CURA-) CURAGEN CORP.
PI	Shimkets RA, Leach M;
DR	WPI; 2001-465210/50.
XX	
PT	Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
PT	oncogenes and histones, useful for diagnosing and treating, e.g.
PT	cancer, autoimmune diseases and infections -
PS	Claim 1; Page 2680; 4143pp; English.
XX	
CC	The present invention relates to oligonucleotides encoding polymorphic
CC	variants of proteins related to amylases, amyloid proteins, angiotensin,
CC	apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,
CC	histones, kinases, colony stimulating factors, complement related
CC	proteins, cytochromes, kinesins, cytokines, interferons, interleukins,
CC	G-protein coupled receptors and thioesterases. The present sequence is
CC	one such oligonucleotide. The oligonucleotides and the peptides encoded
CC	by them may be used in the prevention, diagnosis and treatment of
CC	diseases associated with inappropriate expression of the proteins listed
CC	above. Disorders that may be prevented, diagnosed and/or treated include
CC	multifactorial diseases with a genetic component, such as autoimmune
CC	diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,
CC	systemic lupus erythematosus and Grave's disease), inflammation, cancer
CC	(e.g. cancers of the bladder, brain, breast, colon and kidney,
CC	leukaemia), diseases of the nervous system and an infection of pathogenic
CC	organisms.
XX	
SQ	Sequence 50 BP; 24 A; 5 C; 4 G; 17 T; 0 other;
XX	
Query Match	0.6%; Score 21.6; DB 22; Length 50;
Best Local Similarity	75.0%; Pred. No. 4.4e+04;
Matches 27; Conservative	0; Mismatches 9; Indels 0; Gaps 0;
OY	2567 ttcttcctccttttcttcgaaaaagaaataa 2602                                     36 TATTTACTCTCTTTTTTTTTTAAGAAAGGAAAAA 1
RESULT 15	
AAV83644/C	
ID	AAV83644 standard; DNA; 35 BP.
AC	AAV83644;
XX	
DT	01-MAR-1999 (first entry)
XX	
DE	Oligonucleotide used in the construction of assay plasmids.
XX	
KM	Repetitive sequence; carcinogenic; human dietary component;
XX	DNA instability; cancer; diet; primer; ss.
OS	Synthetic.
XX	
PN	WO9845476-A1.
PD	15-OCT-1998.
XX	
PF	08-APR-1998; 98WO-GB00869.
XX	

XX	08-APR-1997:	97GB-0007141.
XX	(FOOD-) FOOD RES INST.	
PA	Schweizer M;	
PI		
XX	WPI: 1999-024011/02.	
DR		
PT	Assay for testing the carcinogenic properties of a test substance	-
PT	by introduction of a reporter gene expression vector containing a	
PT	repetitive DNA sequence that is unstable in cancer cells	
XX		
PS	Disclosure; Page 17: 103pp: English.	
XX		
CC	The present sequence represents an oligonucleotide used in the	
CC	construction of assay plasmids, which are used in the course of the	
CC	invention. The specification describes an assay for testing the	
CC	carcinogenic properties of a test substance. The assay comprises	
CC	introducing into cells a reporter gene expression vector comprising a	
CC	repetitive DNA sequence which exhibits instability in cancer cells,	
CC	whereby instability of the repetitive DNA sequence affects expression of	
CC	the reporter gene, exposing the resulting cells to the test substance	
CC	and determining whether the test substance is carcinogenic or	
CC	anti-carcinogenic by comparing the frequency of reporter gene expression	
CC	in the resulting cells with the frequency of reporter gene expression in	
CC	cells which have not been exposed to the test substance. The assay can	
CC	be used to identify human dietary components that protect against DNA	
CC	instability, and therefore some types of cancer, and can be used to	
CC	contribute to the scientific basis for a healthy diet.	
xx		
SO	Sequence 35 BP; 22 A; 5 C; 6 G; 2 T; 0 other;	
Query Match	0.6%; Score 21.4; DB 20; Length 35;	
Best Local Similarity	80.6%; Pred. No. 4e+04;	
Matches 25; Conservative 0; Mismatches	6; Indels 0; Gaps 0;	
QY	2561 cccagcttcctcctcttttcttttcbaa 2591	
DB	33 CCGGGCGCTTTTATTTTTTTTTTTCGAA 3	

Search completed: September 18, 2002, 01:22:27  
Job time: 8329 sec





**THIS PAGE BLANK (USPTO)**









;; TITLE OF INVENTION: PRD1-CATALYZED DNA REPLICATION SYSTEMS  
;; NUMBER OF SEQUENCES: 89  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Cahill, Sutton & Thomas  
;; STREET: 155 Park One, 2141 E. Highland Ave.  
;; CITY: Phoenix  
;; STATE: Arizona  
;; COUNTRY: U.S.A.  
;; ZIP: 85016  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Diskette, 5.25 inch, 1.2 Mb  
;; COMPUTER: Packard Bell (IBM PC/AT compatible)  
;; OPERATING SYSTEM: MS-Dos, Version 5.0  
;; SOFTWARE: WordPerfect Version 5.1  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/208,486  
;; FILING DATE:  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 07/869,916  
;; FILING DATE: April 14, 1992  
;; APPLICATION NUMBER: Japan 240525/91  
;; FILING DATE: August 26, 1991  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Janelle Faunce Raupp  
;; REGISTRATION NUMBER: 30,485  
;; REFERENCE/DOCKET NUMBER: #3954-A-7  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (602) 956-7000  
;; TELEFAX: (602) 495-9475  
;; INFORMATION FOR SEQ ID NO: 57:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 40 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: Other nucleic acid (synthetic DNA)  
;; US-08-208-486-57

Query Match 0.5%; Score 20.2; DB 1; Length 40;  
Best Local Similarity 75.8%; Pred. No. 8.2e+03;  
Matches 25; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

OY 122 gctactctctctggaagggaagratcccc 154  
Db 33 gcttagtcttggggaggggacgatatcccc 1

RESULT 12  
US-08-284-784-17  
;; Sequence 17, Application US/08284784  
;; Patent No. 5629172  
;; GENERAL INFORMATION:  
;; APPLICANT: MASCARENHAS, DESMOND  
;; APPLICANT: ZHANG, YANG  
;; APPLICANT: OLSEN, PAMELA S.  
;; APPLICANT: OLSEN, DAVID R.  
;; APPLICANT: CARRILLO, PEDRO A.  
;; TITLE OF INVENTION: EXPRESSION OF FUSION POLYPEPTIDES  
;; TITLE OF INVENTION: TRANSPORTED OUT OF THE CYTOPLASM WITHOUT LEADER SEQUENCES  
;; NUMBER OF SEQUENCES: 44  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: MORRISON & FOERSTER  
;; STREET: 755 Page Mill Road  
;; CITY: Palo Alto  
;; STATE: California  
;; COUNTRY: USA  
;; ZIP: 94304-1018  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS

;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/284,784  
;; FILING DATE: 02-AUG-1994  
;; CLASSIFICATION: 530  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: PARK, FREDIE K.  
;; REGISTRATION NUMBER: 35,636  
;; REFERENCE/DOCKET NUMBER: 22095-20275.20  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (415) 813-5600  
;; TELEFAX: (415) 494-0792  
;; TELEX: 706141  
;; INFORMATION FOR SEQ ID NO: 17:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 46 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; US-08-284-784-17

Query Match 0.5%; Score 20.2; DB 1; Length 46;  
Best Local Similarity 68.3%; Pred. No. 9.1e+03;  
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

OY 1332 cctgatgctcttttttgatgctgacatgtacaagcctct 1272  
Db 6 ccttcgtcttcttcacaggggtgacctggcgcaagatct 46

RESULT 13  
US-08-854-811-17  
;; Sequence 17, Application US/08854811  
;; Patent No. 5914254  
;; GENERAL INFORMATION:  
;; APPLICANT: Mascarenhas, Desmond  
;; APPLICANT: Zhang, Yang  
;; APPLICANT: Olson, Pamela S.  
;; APPLICANT: Olsen, David R.  
;; APPLICANT: Cohen, Pedro A.  
;; TITLE OF INVENTION: EXPRESSION OF FUSION POLYPEPTIDES  
;; TITLE OF INVENTION: TRANSPORTED OUT OF THE CYTOPLASM WITHOUT LEADER  
;; NUMBER OF SEQUENCES: 49  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: MORRISON & FOERSTER  
;; STREET: 755 PAGE MILL ROAD  
;; CITY: Palo Alto  
;; STATE: CA  
;; COUNTRY: USA  
;; ZIP: 94304-1018  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Diskette  
;; COMPUTER: IBM compatible  
;; OPERATING SYSTEM: Windows  
;; SOFTWARE: FastSeq for Windows Version 2.0b  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/854,811  
;; FILING DATE: 12-MAY-1997  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/284,784  
;; FILING DATE: 02-AUG-1994  
;; APPLICATION NUMBER: 08/100,744  
;; FILING DATE: 02-AUG-1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Buffinger, Nicholas S  
;; REGISTRATION NUMBER: 39,124  
;; REFERENCE/DOCKET NUMBER: 22095-20275.21  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 650-813-5600  
;; TELEFAX: 650-494-0792





; INDIVIDUAL ISOLATE: Adenovirus type-2 IX (start site  
; INDIVIDUAL ISOLATE: 3575)  
US-08-171-389-576

Query Match 0.5%; Score 20.2; DB 1; Length 50;  
Best Local Similarity 75.8%; Pred. No. 9.6e+03;  
Matches 25; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
QY 3541 ttagggttgagggaatatattgaggaggct 3573  
||| ||||| ||||| ||||| |||||  
Db 3 TTAAGGCTGGGAAAGAAATATATAAGTGGGGCT 35

Search completed: September 18, 2002, 00:00:45  
Job time: 5692 sec

**THIS PAGE BLANK (USPTO)**



```
c 32 22.6 0.6 48 37 US-10-017-974-36656 Sequence 36656, A
33 22.6 0.6 50 29 US-09-726-172A-102 Sequence 102, App
34 22.4 0.6 25 17 US-09-396-196F-83095 Sequence 83095, A
35 22.4 0.6 40 19 US-09-522-303-489 Sequence 489, App
36 22.4 0.6 41 74 US-60-353-790-1521 Sequence 1521, App
37 22.4 0.6 48 37 US-10-017-974-23096 Sequence 23096, A
38 22.4 0.6 50 14 US-09-078-617-23096 Sequence 23096, A
39 22.2 0.6 64 64 US-60-253-378-27503 Sequence 27503, A
40 22.2 0.6 48 22 US-09-572-021-4810 Sequence 4910, App
41 22.2 0.6 48 37 US-10-017-974-35315 Sequence 35315, A
42 22.2 0.6 50 7 US-08-326-514-10 Sequence 10, Appl
43 22.2 0.6 50 11 US-08-798-074-3200 Sequence 3200, App
44 22.2 0.6 50 11 US-08-798-074B-3200 Sequence 3200, App
45 22.2 0.6 50 29 US-09-755-374A-2636 Sequence 2636, App
```

## ALIGNMENTS

```
RESULT 1
US-10-003-354-6
; Sequence 6, Application US/10003354
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
; FILE REFERENCE: RTS-0348
; CURRENT APPLICATION NUMBER: US/10/003.354
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 6
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-003-354-6

Query Match 0.7%; Score 26; DB 37; Length 26;
Best Local Similarity 100.0%; Pred. No. 5.4e+04;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 cgcgggttcgtgaagacgttgg 326
Db 1 cgcgggttcgtgaagacgttgg 26

RESULT 2
US-09-755-374A-25691
; Sequence 25691, Application US/09755374A
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin
; APPLICANT: Shmukets, Richard A.
; TITLE OF INVENTION: Nucleic Acids Containing Single Nucleotide Polymorphisms and Meth
; FILE REFERENCE: 15966-611
; CURRENT APPLICATION NUMBER: US/09/755.374A
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/174962
; PRIOR FILING DATE: 2000-01-07
; NUMBER OF SEQ ID NOS: 28742
; SEQ ID NO 25691
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (25)...(0)
; OTHER INFORMATION: 1 of 2 allelic variants (25692 is other entry)
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
```

```
; OTHER INFORMATION: Accession number cg44004721
US-09-755-374A-25691
```

```
Query Match 0.7%; Score 25; DB 29; Length 50;
Best Local Similarity 69.4%; Pred. No. 1.4e+05;
Matches 34; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
```

```
Qy 3479 ttttttataattactattatgatgatattgaagttattaa 3527
Db 1 ttttttttttttttttttttttttttttttttaagcatttttaagtgcttactaa 49
```

```
RESULT 3
US-09-342-217-4074
; Sequence 4074, Application US/09342217
; GENERAL INFORMATION:
; APPLICANT: Craig A. Rosen, et. al.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products - PO40
; NUMBER OF SEQUENCES: 5660
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc.
; STREET: 9410 Key West Avenue
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4MB storage
; OPERATING SYSTEM: HP Vectra 486/33
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/342.217
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Benson, Bob
; REGISTRATION NUMBER: 30,446
; REFERENCE/DOCKET NUMBER: PO40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 309-8504
; INFORMATION FOR SEQ ID NO: 4074:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 50 Base Pairs.
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-09-342-217-4074

Query Match 0.7%; Score 24.4; DB 17; Length 50;
Best Local Similarity 73.7%; Pred. No. 2e+05;
Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 2562 ccagcttctctctctttttttttctgaaaagaaga 2599
Db 13 CGAGTTTTTTTTTTTTTTTTTTTNNAAAAAANNA 50

RESULT 4
US-09-342-217A-4074
; Sequence 4074, Application US/09342217A
; GENERAL INFORMATION:
; APPLICANT: Rosen, Craig, et al.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products 40
; FILE REFERENCE: PO-40
; CURRENT APPLICATION NUMBER: US/09/342.217A
; CURRENT FILING DATE: 1999-06-29
```

```

1  PRIOR APPLICATION NUMBER: 60/091,170
2
3  PRIOR FILING DATE: 1998-06-30
4
5  NUMBER OF SEQ ID NOS: 5662
6
7  SOFTWARE: PatentIn Ver. 2.0
8
9  SEQ ID NO: 4074
10
11  LENGTH: 50
12
13  TYPE: DNA
14
15  ORGANISM: Homo sapiens
16
17  FEATURE:
18
19  NAME/KEY: misc feature
20
21  LOCATION: (38)
22
23  OTHER INFORMATION: n equals a,t,g, or c
24
25  NAME/KEY: misc feature
26
27  LOCATION: (40)
28
29  OTHER INFORMATION: n equals a,t,g, or c
30
31  NAME/KEY: misc feature
32
33  LOCATION: (47)
34
35  OTHER INFORMATION: n equals a,t,g, or c
36
37  NAME/KEY: misc feature
38
39  LOCATION: (48)
40
41  OTHER INFORMATION: n equals a,t,g, or c
42
43  OS-09-342-217A-4074

```

```
-Query Match      0.7%: Score 20.4; DB 17; Length 50;
Best Local Similarity 73.7%: Pred. No. 2e+05;
Matches 28; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
```

```

RESULT      5
US-09-755-374A-17699
Sequence: 17699, Application US/09755374A
GENERAL INFORMATION:
APPLICANT: Leach, Martin
APPLICANT: Shinkets, Richard A.
TITLE OF INVENTION: Nucleic Acids Containing Single Nucleotide Polymorphisms and Meth
TITLE OF INVENTION: Use Thereof
FILE REFERENCE: 15966-611
CURRENT APPLICATION NUMBER: US/09/755, 374A
CURRENT FILING DATE: 2001-01-08
PRIOR APPLICATION NUMBER: 60/174962
PRIOR FILING DATE: 2000-01-07
NUMBER OF SEQ ID NOS: 28742
SEQ ID NO 17699
LENGTH: 50
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: (26)...(0)
OTHER INFORMATION: 1 of 2 allelic variants (17700 is other entry)
NAME/KEY: misc_feature
LOCATION: (25)...(26)
OTHER INFORMATION: Nucleotide deleted between bases 25 and 26
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: Accession number CG43932310
US-09-755-374A-17699

```

```

Query Match 0.6% Score 23.8 DB 29; Length 50;
Best Local Similarity 72.1% Pred. No.2.8e+05
Matches 31; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Oy 3470 ttctgtcatttttttccataattcattcattatgatgtatt 3512
      ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
db 7 ttttttttttttttttttttttttttttttttttttttt 49
      ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

RESULT 36
US-09-396-196F-83096
: Sequence 83096, Application US/09396196F
: GENERAL INFORMATION:
: APPLICANT: Michael Miltmann
: APPLICANT: David Mack
: APPLICANT: David Lockhart
: APPLICANT: Affymetrix, Inc.
: TITLE OF INVENTION: Methods of Genetic Analysis
: FILE REFERENCE: 3101.1
: CURRENT APPLICATION NUMBER: US/09/396,196F
: CURRENT FILING DATE: 2001-09-15
: PRIOR APPLICATION NUMBER: 60/100,678
: PRIOR FILING DATE: 1998-09-17
: NUMBER OF SEQ ID NOS: 127806
: SOFTWARE: FASTSEQ for Windows Version 4.0
: SEQ ID NO 83096
: LENGTH: 25
: TYPE: DNA
: ORGANISM: mus musculus
US-09-396-196F-83096

```

	Query Match	Score 23.4	DB 17	Length 25
	Best Local Similarity	96.0%	Pred. No. 2.5e+05	
	Matches 24	Conservative 0	Mismatches 1	Indels 0
Gy	2110 agccctgcgccagcgaatgctgaat	2134		
db	1 agccctgcgccagcgaatgctgaat	25		

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```



```

RESULT 11
PCT-US01-47856-5024/C
; Sequence 5024, Application PC/TUS0147856
; GENERAL INFORMATION:
; APPLICANT: BIOCARDIA, INC.
; APPLICANT: Wohlgenuth, Jay
; APPLICANT: Quentermuth, Thomas
; APPLICANT: Johnson, Frances
; APPLICANT: Fry, Kirk
; APPLICANT: Matcuk, George
; APPLICANT: Prentice, James
; APPLICANT: Phillips, Julie
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; APPLICANT: Altman, Peter
; TITLE OF INVENTION: LEUKOCYTE EXPRESSION PROFILING
; FILE REFERENCE: 50661200140
; CURRENT APPLICATION NUMBER: PCT/US01/47856
; CURRENT FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/241,994
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 8832
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5024
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
PCT-US01-47856-5024

Query Match 0.6%, Score 23.2; DB 1; Length 50;
Best Local Similarly 70.5%; Pred. No. 4e+05;
Matches 31; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1214 gactcttaacaagacatcccgatgctcttttttgatgcgca 1257
Db 44 GAGTGCCTATGAGAAATCTCAAAAGGTATTGTGTTGGGTCGAGA 1

RESULT 12
US-09-755-374A-6837/C
; Sequence 6837, Application US/09755374A
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin
; TITLE OF INVENTION: Nucleic Acids Containing Single Nucleotide Polymorphisms and Methods
; TITLE OF INVENTION: Use Thereof
; FILE REFERENCE: 15866-611
; CURRENT APPLICATION NUMBER: US/09/755,374A
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/174962
; PRIOR FILING DATE: 2000-01-07
; NUMBER OF SEQ ID NOS: 28742
; SEQ ID NO 6837
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (26)..(0)
; OTHER INFORMATION: 1 of 2 allelic variants (6838 is other entry)
; NAME/KEY: misc_feature
; LOCATION: (25)..(26)
; OTHER INFORMATION: Nucleotide deleted between bases 25 and 26
; NAME/KEY: misc_feature
; LOCATION: (0)..(0)
; OTHER INFORMATION: Accession number CG44911096
; US-09-755-374A-6837

```

```

QY 2555 ccaccctccagcttcctctctctctctctctctctga 2590
    ||| ||||| ||| | ||| ||||| ||||| |
Db 44 CCAAACCCAGATTTGTACTTTTCTTTTCTTTCTTCA 9
    ||| ||||| ||| | ||| ||||| ||||| |

RESULT 13
US-09-755-374A-13433
; Sequence 13433, Application US/09755374A
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin
; APPLICANT: Shinkets, Richard A.
; TITLE OF INVENTION: Nucleic Acids Containing Single Nucleotide Polymorphisms and M
; TITLE OF INVENTION: Use Thereof
; FILE REFERENCE: 15966-611
; CURRENT APPLICATION NUMBER: US/09/755, 374A
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/174962
; PRIOR FILING DATE: 2000-01-07
; NUMBER OF SEQ ID NOS: 28742
; SEQ ID NO 13433
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (26)...(0)
; OTHER INFORMATION: 1 of 2 allelic variants (13434 is other entry)
; NAME/KEY: misc_feature
; LOCATION: (25)...(26)
; OTHER INFORMATION: Nucleotide deleted between bases 25 and 26
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: Accession number cg44002450
US-09-755-374A-13433

Query Match 0.6%, Score 23.2, DB 29; Length 50;
Best Local Similarity 77.8%, Pred. No. 4e+05;
Matches 28; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2563 cagcttctctctctctctctctctctctctctctga 2598
    ||||| ||| ||| ||||| ||||| ||||| |
Db 15 cagcttctctctctctctctctctctctctctctta 50
    ||||| ||| ||| ||||| ||||| ||||| |

RESULT 14
US-08-346-731-6670
; Sequence 6670, Application US/08346731
; GENERAL INFORMATION:
; APPLICANT: Craig A. Rosen, et. al.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products - P016
; NUMBER OF SEQUENCES: 12477
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc.
; STREET: 9410 Key West Avenue
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
; COMPUTER: HP Vectra 486/33
; OPERATING SYSTEM: MSDOS version 6.2
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/346,731
; FILING DATE:
; CLASSIFICATION: 435

```

1 PRIOR APPLICATION DATA:  
2 APPLICATION NUMBER:  
3 FILING DATE:  
4 ATTORNEY/AGENT INFORMATION:  
5 NAME: Benson, Bob  
6 REGISTRATION NUMBER: 30,446  
7 REFERENCE/DOCKET NUMBER: P01  
8 TELECOMMUNICATION INFORMATION:  
9 TELEPHONE: (301) 309-8504  
10 TELEFAX: (301) 309-8512  
11 INFORMATION FOR SEQ ID NO: 6670:  
12 SEQUENCE CHARACTERISTICS:  
13 LENGTH: 50 base pairs  
14 TYPE: nucleic acid  
15 STRANDEDNESS: double  
16 TOPOLOGY: linear  
17  
18 US-08-346-731-6670

Query Match	0.6%	Score 23	DB 7	Length 50
Best Local Similarity	66.7%	Pred. No.	4.6e+05	
Matches 32	Conservative	0	Mismatches 16	Indels 0
				Gaps 0

```
OY      2556 caccctccagcgttcctcttctttttttctgaaaaaaaggaaaag   2603
          ||    |||  || | ||||| | | | | | | | | | | |
DB       3 CANAGCCCTTTT TTTTTTTTTTTT TTTTAAATAAAAAAAGG   50
```

RESULT 15  
US-08-420-856-6670  
: Sequence 6670, Application US/08420856

? APPLICANT: Rosen, Craig A.  
 ? APPLICANT: Ruben, Steve M.  
 ? APPLICANT: Dillon, Patrick J.  
 ? APPLICANT: Li, Haodong  
 ? APPLICANT: Haseltine, William A.  
 ? TITLE OF INVENTION: Human Genes, Sequences, and Expression Products - 16  
 ? NUMBER OF SEQUENCES: 12477  
 ? CORRESPONDENCE ADDRESS:  
 ? ADDRESSEE: Carella, Byrne, Bain, Gillfillan, Cecchi, Stewart, & Olstein  
 ? STREET: 6 Becker Farm Road  
 ? CITY: Roseland  
 ? STATE: New Jersey  
 ? COUNTRY: USA  
 ? ZIP: 07068  
 ? COMPUTER READABLE FORM:  
 ? MEDIUM TYPE: Diskette, 3.50 inch, 1.4mb storage  
 ? COMPUTER: HP Vectra 486/33  
 ? OPERATING SYSTEM: MSDOS version 5.0  
 ? SOFTWARE: ASCII Text  
 ? CURRENT APPLICATION DATA:  
 ? APPLICATION NUMBER: US/08/420,856  
 ? FILING DATE:  
 ? CLASSIFICATION: 536  
 ? PRIOR APPLICATION DATA:  
 ? APPLICATION NUMBER:  
 ? FILING DATE:  
 ? ATTORNEY/AGENT INFORMATION:  
 ? NAME: Olstein, Elliot  
 ? REGISTRATION NUMBER: 24,025  
 ? REFERENCE/DOCKET NUMBER: 325800-259  
 ? TELECOMMUNICATION INFORMATION:  
 ? TELEPHONE: (201) 994-1700  
 ? TELEFAX: (201) 994-1744  
 ? INFORMATION FOR SEQ ID NO: 6670:  
 ? SEQUENCE CHARACTERISTICS:  
 ? LENGTH: 50 base pairs  
 ? TYPE: nucleic acid  
 ? STRANDEDNESS: double  
 ? TOPOLOGY: linear  
 ?

	Query Match	0.6%	Score 23	DB 8	Length 50
	Best Local Similarity	66.7%	Pred. No.	4.6e+05	
	Matches 32	Conservative	0	Mismatches 16	Indels 0
	Gaps				0
Oy	2556 caactccagcttcctcctcttttcttgaaagaagaag	2603			
Db	3 CANAGCCCTTTTITTTTTTTTTTTTTTTAAAAAAAAG	50			

Search completed: September 18, 2002, 02:37:20  
Job time: 9827 sec





**THIS PAGE BLANK (USPTO)**



;; PRIOR FILING DATE: 2001-06-08  
;; NUMBER OF SEQ ID NOS: 9190  
;; SOFTWARE: PatentIn version 3.1  
;; SEQ ID NO 5024  
;; LENGTH: 50  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-10-131-831-5024

Query Match 0.6%; Score 23.2; DB 6; Length 50;  
Best Local Similarity 70.5%; Pred. No. 7.4e+04;  
Matches 31; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1214 gactcttaacagacacccctgctgctcttttttgatcctga 1257  
Db 44 GAATGCTATATAGAAATCTCAAAAGTATTGTTCGCTCACA 1

RESULT 3  
US-10-189-360-50  
; Sequence 50, Application US/10189360  
; GENERAL INFORMATION:

APPLICANT: Baird, J. Andrew  
Sosnowski, Barbara A.  
TITLE OF INVENTION: COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS  
FOR THERAPE

NUMBER OF SEQUENCES: 128  
CORRESPONDENCE ADDRESS:  
ADDRESS: SEED and BERRY LLP  
STREET: 6300 Columbia Center, 701 Fifth Avenue  
CITY: Seattle  
STATE: Washington  
COUNTRY: USA  
ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/189,360  
FILING DATE: 02-Jul-2002

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/718,904  
FILING DATE: 24-SEP-1996

ATTORNEY/AGENT INFORMATION:  
NAME: Nottenburg Ph.D., Carol

REGISTRATION NUMBER: 39,317

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 50:

SEQUENCE CHARACTERISTICS:

LENGTH: 45 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

FEATURE:  
NAME/KEY: (Seq4g1y)2

LOCATION: 3..45

SEQUENCE DESCRIPTION: SEQ ID NO: 50:

US-10-189-360-50

Query Match 0.6%; Score 22.6; DB 6; Length 45;  
Best Local Similarity 75.7%; Pred. No. 1e+05;  
Matches 28; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 401 atggcgtgcgcctcccgccggtcgtcttcgctgc 437  
Db 3 ATGGCTCGTCGTGCGGCTGTGTCGTGCGGCTG 39

RESULT 4  
US-09-396-196G-83095

; Sequence 83095, Application US/09396196G  
; GENERAL INFORMATION:

APPLICANT: Michael Miltmann

APPLICANT: David Mack

APPLICANT: David Lockhart

APPLICANT: Affimetrix, Inc.

TITLE OF INVENTION: Methods of Genetic Analysis

FILE REFERENCE: 3101.1

CURRENT APPLICATION NUMBER: US/09/396,196G

CURRENT FILING DATE: 1999-09-15

PRIOR APPLICATION NUMBER: 60/100,678

PRIOR FILING DATE: 1998-09-17

NUMBER OF SEQ ID NOS: 127806

SOFTWARE: FastSeq for windows Version 4.0

SEQ ID NO 83095

LENGTH: 25

TYPE: DNA

ORGANISM: mus musculus

US-09-396-196G-83095

Query Match 0.6%; Score 22.4; DB 5; Length 25;  
Best Local Similarity 95.8%; Pred. No. 8.9e+04;  
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2057 agcctcagaagacctggaacaaga 2080  
Db 2 agcctcagaagacctggaacaaga 25

RESULT 5  
US-10-131-831-7656/C

; Sequence 7656, Application US/10131831  
; GENERAL INFORMATION:

APPLICANT: Wohlgenuth, Jay

APPLICANT: Fry, Kirk

APPLICANT: Woodward, Robert

APPLICANT: Ly, Ngoc

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING

FILE REFERENCE: 506612000121

CURRENT APPLICATION NUMBER: US/10/131,831

CURRENT FILING DATE: 2002-08-05

PRIOR APPLICATION NUMBER: US 10/006,290

PRIOR FILING DATE: 2001-10-22

PRIOR APPLICATION NUMBER: US 60/296,764

PRIOR FILING DATE: 2001-06-08

NUMBER OF SEQ ID NOS: 9190

SOFTWARE: PatentIn version 3.1

SEQ ID NO 7656

LENGTH: 50

TYPE: DNA

ORGANISM: Homo sapiens

US-10-131-831-7656

Query Match 0.6%; Score 22; DB 6; Length 50;  
Best Local Similarity 83.3%; Pred. No. 1.5e+05;  
Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1638 gagacactgtcagtcagtcagccagcgt 1667  
Db 48 GAGACAGGCTCTCACTGATATGCCCAAGCT 19

RESULT 6

```

RESULT 10
US-10-027-632-177620/c
; Sequence 177620, Application US/10027632
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide

```

RESULT 12  
US-10-055-728-32

QY 2939 ggttgcttttctaatagtgaagacttaccaatgaattt 2977  
| | | | | | | | | | : | | | | | | | | | |



